Phathom Pharmaceuticals, Inc. Common Stock (PHAT) Stock
Key stats
- Market cap
- $510.51M
- Price / Earnings ratio
- -5.3x
- EPS (TTM)
- -$1.01
- Volume
- Loading
- 52-week high
- $18.31
- 52-week low
- $5.02
Source: third-party data provider, as of November 13, 2026
Compare with PHAT
Recent news

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
PHAT

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
PHAT

PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
PHAT

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
PHAT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.52
- MACD 12/26/9
- -0.46
- EMA 9 of MACD
- -0.49
- MACD histogram
- 0.03
- SMA 50
- $7.09
- Price below SMA 50
- EMA 50
- $7.01
- Price below EMA 50
- SMA 200
- $10.10
- Price below SMA 200
- EMA 200
- $10.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
PHAT

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
PHAT

PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
PHAT

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
PHAT

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
PHAT

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
PHAT

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
PHAT

Phathom Pharmaceuticals Q2 Earnings Call Highlights
Phathom Pharmaceuticals Q2 Earnings Call Highlights
PHAT

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
PHAT

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
PHAT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Phathom Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven L. Basta M.B.A. | CEO, President & Director | 1966 |
| Mr. David A. Socks | Co-Founder | 1975 |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder | 1960 |
| Mr. Sanjeev Narula | Chief Financial & Business Officer | 1961 |
| Ms. Anne Marie Cook Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1962 |
| Mr. Jonathan Bentley | Senior VP and Head of Sales, Operations & Training | — |
| Mr. Robert Breedlove | VP of Finance & Principal Accounting Officer | — |
| Mr. Eric Sciorilli | Director of Business Development & Investor Relations | — |
| Mr. Bill Aprea J.D. | Senior VP, Chief Compliance Officer & Deputy Chief Legal Officer | — |
| Ms. Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.52
- MACD 12/26/9
- -0.46
- EMA 9 of MACD
- -0.49
- MACD histogram
- 0.03
- SMA 50
- $7.09
- Price below SMA 50
- EMA 50
- $7.01
- Price below EMA 50
- SMA 200
- $10.10
- Price below SMA 200
- EMA 200
- $10.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $12.00
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.8 | +10.3 | ||||||||||
| 2022 | -15.9 | +3.6 | -24.9 | -9.1 | -48.6 | +17.4 | +1.5 | -5.8 | +26.8 | +7.5 | -9.4 | +14.0 |
| 2023 | -0.5 | -27.0 | -20.8 | +44.2 | +5.9 | +23.1 | +14.3 | -4.7 | -28.6 | -8.4 | -27.3 | +25.1 |
| 2024 | -26.9 | +60.7 | -0.7 | -14.8 | +1.7 | -0.3 | +9.3 | +44.5 | +11.3 | +1.0 | -51.5 | -6.8 |
| 2025 | -18.3 | -2.0 | +20.3 | -16.2 | +26.5 | +106.7 | -3.5 | +45.9 | -0.7 | +10.3 | +13.8 | +11.0 |
| 2026 | -13.0 | -9.1 | -3.1 | +0.5 | -20.1 | +17.4 | -17.0 | +6.6 | -22.3 | -18.9 | +6.1 |



